# PathMap Report Trace Context: #00000040
Hypothesis: Can inhaled COVID-19 vaccinations be used to help treat COPD?
Author: Joshua Dungan (PathMap.org)
License: 'THE GLOBAL HUMANITARIAN PROPRIETARY LICENSE (VERSION 1.0.1)' https://pathmap.org/license.pdf
Zenodo DOI: 10.5281/zenodo.21285955
Full provenance JSON trace: https://pathmap.org/download.php/?id=40
==================================================

SYSTEM NOTE: The eight-digit ID numbers (e.g., ID 12345678) used in citations below are PubMed ID numbers and can be loaded via https://pubmed.ncbi.nlm.nih.gov/{ID}/ for verification.

==================================================

## Primary Synthesis & Clinical Bottom-Line
Inhaled COVID-19 vaccination platforms, designed to bypass the limitations of systemic intramuscular administration by inducing mucosal IgA and tissue-resident memory T cells (Trm), are currently assessed for their utility in high-risk patients, including those with COPD. The literature supports these platforms as vital strategies to mitigate viral-triggered exacerbations, which are critical events in COPD morbidity.

## Plausibility Verdicts
- Evaluation 1: Inhaled COVID-19 vaccinations serve as a preventive tool to mitigate viral-induced exacerbations in COPD rather than as a therapeutic treatment for the obstructive pulmonary disease itself.
- Evaluation 2: Inhaled COVID-19 vaccines are a promising strategy to induce localized mucosal immunity, which could be highly beneficial for COPD patients, though clinical human data for this specific therapeutic application remain limited.
- Evaluation 3: No, inhaled COVID-19 vaccines cannot treat COPD. They are used to prevent viral infections that could trigger exacerbations of your condition.

## Novel & Overlooked Insights
- RSV infection in adults with chronic lung disease has been associated with a higher disease burden compared to influenza or SARS-CoV-2.
- Intranasal and pulmonary "pull" vaccination strategies are effective at inducing secretory IgA and lung-resident T-cell responses that are typically absent following intramuscular injection.
- The use of cationic ferritin nanoparticles or adenoviral vectors for intranasal delivery can overcome pre-existing immunity against viral vaccine vectors.
- Specific biomarkers, such as the CCL5/CCR4 signaling axis, are being identified as modulators of immune cell migration following mucosal immunization.
- There is a persistent "interferon gap" in the elderly, characterized by a kinetic delay in innate antiviral signaling, which mucosal platforms aim to bridge.
- The use of codon-pair deoptimization (CPD) in live-attenuated vaccines represents a novel safety mechanism for developing inhaled platforms.
- Some evidence suggests that high-dose systemic corticosteroids may paradoxically increase mortality in COVID-19 ARDS, reinforcing the need for targeted, localized prophylactic strategies like mucosal vaccination.
- Evidence suggests that the mucosal immune system in the respiratory tract can be specifically engaged to mitigate infection-driven COPD exacerbations.
- Inhaled delivery mechanisms for biologics can reduce the required dosage of therapeutic agents while bypassing gastrointestinal degradation.
- Lipid-based nanocarriers have demonstrated the ability to cross pulmonary mucosal barriers, a critical feature for both therapeutic and prophylactic agents.
- Advanced nebulization techniques (mesh versus jet nebulizers) significantly impact the efficiency of pulmonary delivery, which is vital for the clinical success of inhaled therapeutics.
- There is a clear distinction between the immunogenicity profiles of intramuscular (systemic IgG) and mucosal (respiratory IgA) vaccinations, with the latter showing promise for enhancing local airway resilience.
- Inhaled heparin is emerging as a versatile therapeutic option, given its established role in managing respiratory infections including COVID-19 and its potential use in asthma and COPD.
- Clinical data indicate that SARS-CoV-2 infection is associated with different mortality and inflammatory markers in patients with COPD versus other respiratory viruses.
- Nanotechnology integration into inhalers allows for precise, patient-centric dosing, which could improve adherence in chronic populations.
- A "virus-agnostic" immunomodulatory platform, distinct from traditional vaccines, is proposed to restore mucosal immune competence in the elderly (ID: 42347596).
- Intranasal vaccination with PIV5-vectored platforms has been evaluated in animal models, showing protection against challenge without necessarily relying on serum neutralizing antibodies (ID: 41863913).
- Probiotic supplementation has shown potential to reduce systemic inflammation and improve patient-reported outcomes in COPD (ID: 42286603).
- The gut-lung axis is increasingly recognized as a target, with researchers identifying cross-kingdom microbiome interactions that influence COPD outcomes (ID: 42324603).
- Sex-specific differences exist in neutrophil transcriptional programs in COPD, which may necessitate sex-dependent therapeutic strategies (ID: 42281812).
- There is a significant heterogeneity in clinical outcomes for ACOS (Asthma-COPD overlap), with newer glucose-lowering agents showing potential to modify risk (ID: 42376494).

## Extracted Custom Discoveries
### Suggested Experiments
- Evaluate the duration of mucosal IgA maintenance following intranasal boosting in COPD-specific murine models.
- Compare the efficacy of heterologous prime-pull strategies using subunit proteins vs. mRNA-LNPs in reducing viral load in COPD-derived iALI models.
- Assess whether pre-vaccination with intranasal NDV-HXP-S reduces the inflammatory cytokine surge typically observed in COPD airways following viral challenge.
- Assess sIgA production in COPD patient airways following intranasal administration of multiepitope SARS-CoV-2 nanovaccines.
- Compare the efficacy of nebulized vs intramuscular COVID-19 vaccination in preventing exacerbations in COPD murine models.
- Evaluate the stability of lyophilized COVID-19 nanovaccines in COPD-derived sputum samples in vitro.
- Investigate the efficacy of inhaled PIV5-vectored vaccines in preventing viral-triggered acute exacerbations in COPD murine models.
- Evaluate the impact of mucosal immune training on the frequency of secondary bacterial infections in COPD patients.

### Suggested Studies
- Multi-center longitudinal trial to determine if inhaled vaccine boosters reduce the rate of moderate-to-severe exacerbations in GOLD Group E patients.
- Comparative effectiveness study of intranasal versus intramuscular vaccine boosters on the incidence of secondary bacterial co-infections in post-acute COVID-19 COPD patients.
- Phase I/II clinical trial of dual-phase virus-agnostic immunomodulatory platforms (AIR strategy) for high-risk elderly COPD populations.
- A multi-center randomized trial comparing the incidence of secondary bacterial infections in COPD patients receiving inhaled vs. systemic COVID-19 vaccines.
- A prospective observational study on long-term safety and mucosal immune durability of intranasal COVID-19 boosters in patients with GOLD Stage III-IV COPD.
- Conduct a longitudinal study tracking the long-term impact of mucosal vaccine-induced Trm cells on the frequency and severity of COPD exacerbations in the elderly.
- Assess the safety and mucosal antibody response of next-generation inhaled vaccine platforms in COPD patients with existing lung barrier dysfunction.

### Swansons Literature Based Discovery Candidates
- Discovered Hypothesis (A to C): Inhaled delivery of saponin-based ISCOMATRIX formulations could be repurposed to enhance mucosal IgA in COPD patients against non-COVID viral triggers of exacerbations.
Literature A (Origin): Radix pseudostellariae saponins enhance immune responses (Source: 42353538) and Mucosal delivery of Pleurotus-based ISCOMATRIX elicits robust responses against Streptococcus pneumoniae (Source: 42375405).
Literature C (Target): COPD patients prone to recurrent viral/bacterial exacerbations (Source: 41871621).
The Intersecting Bridge B: Mucosal IgA induction and chemokine signaling (CCL5/CCR4).
Biological Rationale: Given that mucosal immunity is deficient in COPD and exacerbations are triggered by common pathogens, using plant-derived saponin platforms to prime mucosal IgA could provide a generalist strategy to reinforce the airway barrier against various respiratory pathogens.
- Inhaled COVID-19 vaccines may mitigate COPD exacerbations by stabilizing the airway epithelial barrier through non-specific trained immunity.
- Inhaled mucosal vaccines stimulate local IgA and resident T-cells (Source: 41081494)
- COPD exacerbation frequency is driven by chronic inflammation and epithelial damage (Source: 40780470)
- γδ T cell-mediated trained immunity
- Prior viral exposure and vaccination are known to train airway T cells (Source: 41848341), and these cells can limit the inflammatory damage to the epithelium that characterizes COPD exacerbations.
- Inhaled PIV5-vectored vaccines may indirectly prevent the loss of alveolar macrophage efferocytic function by preventing viral-induced secondary inflammation.
- PIV5-vectored vaccines (41863913)
- Alveolar macrophage efferocytic function (42335653)
- IFN-gamma mediated modulation of lung inflammatory tone.
- PIV5 vaccines induce a mucosal Th1-biased cellular profile including IFN-gamma surge; IFN-gamma is a key regulator of macrophage functional polarization in response to inflammation and may protect the metabolic pathways required for efferocytosis (FABP5 axis).

### Contradictions Between Evidences
- There is a notable dispute regarding the utility of systemic corticosteroids in acute COVID-19 settings: ID 42385526 indicates high-dose corticosteroids correlate with higher mortality, whereas other standard care guidelines often support their use in severe respiratory distress, suggesting an urgent need to delineate dosing thresholds specifically for COPD patients with COVID-19.
- There is mixed data regarding the impact of inhaled corticosteroids on COVID-19 severity; some sources suggest they may be beneficial or neutral (Source: 39275934), while historical concerns regarding infection risk exist (Source: 41485772).
- There is a noted divergence in research regarding the impact of different inhaled therapies on severe COVID-19 risk (e.g., ICS-containing triple therapy vs. dual therapy), indicating that while inhalation is a standard route, the specific agent matters significantly (41485772).

### Repurposed Solutions
- The repurposing of 'prime-pull' immunization strategies, originally developed for SARS-CoV-2, could be adapted as a prophylactic regimen to protect patients with COPD against seasonal influenza and RSV, as identified in ID 42399410.
- Inhaled heparin and neutrophil-mimicking nanoparticles (LVX@PLGA@Mem) are being repurposed as targeted therapies for COPD-associated pulmonary inflammation.
- The use of 'Allopriming' and 'AIR' platforms (42347596) repurposed from general elderly immune-rejuvenation could serve as a novel prophylactic strategy for COPD patients prone to recurring exacerbations.

## Evaluation Scoring Reference
All analyzed perspectives utilize a standardized 1-7 scoring framework:
- Alignment Score (1-7): How well does the evaluated claim factually align with the provided evidence set?
  [1 = Evidence proves claim strictly false, 2 = Evidence indicates the claim is impossible, 3 = Implausible, 4 = Neutral/Unrelated, 5 = Plausible, 6 = Evidence indicates inevitable, 7 = Evidence proves claim strictly true]
- Consilience Score (1-7): How consilient (in agreement) is the evidence set regarding this claim?
  [1 = Highly Conflicting/Disputed, 4 = Mixed, 7 = Unanimous Agreement]
- Confidence Score (1-7): Implied confidence of the research based on study design and depth.
  [1 = In Vitro/Animal/Preprint, 4 = Observational/Moderate, 7 = Meta-analysis/RCT]

## Evaluated Perspectives & Findings
### Perspective R1: Claim [Run1 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 5/7
- Consilience Score: 6/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although "Zero Hallucinated Moneyshot Quotes" is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
"Can inhaled COVID-19 vaccinations be used to help treat COPD?"

The provided literature indicates that while inhaled vaccines are being actively investigated to improve respiratory mucosal immunity and reduce viral-induced exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD), they are primarily proposed as a preventive strategy rather than a direct treatment for the underlying pathophysiology of COPD itself.

### [ABSTRACT & REWRITTEN CLAIM]
Inhaled COVID-19 vaccination platforms, designed to bypass the limitations of systemic intramuscular administration by inducing mucosal IgA and tissue-resident memory T cells (Trm), are currently assessed for their utility in high-risk patients, including those with COPD. The literature supports these platforms as vital strategies to mitigate viral-triggered exacerbations, which are critical events in COPD morbidity.

### [INTRODUCTION & JUSTIFICATION]
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent inflammation and susceptibility to severe respiratory exacerbations, often triggered by viral infections. Conventional intramuscular vaccines, while effective at reducing severe systemic outcomes, often fail to induce robust mucosal responses at the site of primary viral entry. The paradigm shift toward intranasal and pulmonary immunization seeks to address this by re-directing the immune response to the respiratory mucosa. As demonstrated by recent research, respiratory infections are major and potentially modifiable triggers of ECOPD, and existing systemic vaccination strategies have limitations regarding their ability to block early infection and transmission. Therefore, the implementation of inhaled vaccination strategies is specifically geared towards "re-directing the immune response to the respiratory mucosa" to provide more comprehensive protection against the "interferon gap" and immunosenescence in high-risk populations.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   RSV infection in adults with chronic lung disease has been associated with a higher disease burden compared to influenza or SARS-CoV-2.
*   Intranasal and pulmonary "pull" vaccination strategies are effective at inducing secretory IgA and lung-resident T-cell responses that are typically absent following intramuscular injection.
*   The use of cationic ferritin nanoparticles or adenoviral vectors for intranasal delivery can overcome pre-existing immunity against viral vaccine vectors.
*   Specific biomarkers, such as the CCL5/CCR4 signaling axis, are being identified as modulators of immune cell migration following mucosal immunization.
*   There is a persistent "interferon gap" in the elderly, characterized by a kinetic delay in innate antiviral signaling, which mucosal platforms aim to bridge.
*   The use of codon-pair deoptimization (CPD) in live-attenuated vaccines represents a novel safety mechanism for developing inhaled platforms.
*   Some evidence suggests that high-dose systemic corticosteroids may paradoxically increase mortality in COVID-19 ARDS, reinforcing the need for targeted, localized prophylactic strategies like mucosal vaccination.

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 41871621 - Application: Evidence supports that respiratory infections are key triggers for exacerbations. "Respiratory infections are major and potentially modifiable triggers of ECOPD"
2. ID: 42368930 - Application: Limits of parenteral vaccines. "Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time."
3. ID: 42368930 - Application: Benefit of heterologous mucosal boosting. "Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission"
4. ID: 41664178 - Application: RSV burden comparison. "RSV infection in patients with CLD revealed higher disease severity compared to influenza and SARS-CoV-2, warranting increased clinical attention for this population."
5. ID: 42399410 - Application: Mechanism of mucosal redirection. "This suggests that i.m. priming of strong immune responses with mRNA-LNPs combined with mucosal pull immunization with a subunit vaccine can re-direct the immune response to the respiratory mucosa."
6. ID: 42365337 - Application: Multiepitope protection. "An i.n. multiepitope adenoviral vaccine incorporating conserved SARS-CoV-2 antigens induces robust mucosal, humoral, and cellular immune responses and confers significant protection following SARS-CoV-2 challenge."
7. ID: 41782833 - Application: COPD susceptibility. "Infection of iALI led to robust viral replication, persistent infection, cilia loss in infected ciliated epithelial cells, increased mucus secretion, and higher inflammatory cytokine release in COPD iALI."
8. ID: 42364994 - Application: Imprinting and boosting. "These findings establish that in mice, intranasal or repeated variant-matched boosting can overcome the effects of imprinting and enhance immunity against SARS-CoV-2 strains."
9. ID: 42378814 - Application: NDV-HXP-S design. "Newcastle disease virus hexapro spike (NDV-HXP-S) is a recombinant vaccine designed to elicit both systemic and mucosal immunity against SARS-CoV-2."
10. ID: 42347596 - Application: Immunomodulatory platform. "This perspective paper proposes a dual-phase, virus-agnostic immunomodulatory platform designed to restore mucosal immune competence and provide a rapid-response intervention for incipient exacerbations."
11. ID: 42385526 - Application: Corticosteroid mortality risk. "In patients with COVID-19 ARDS, high-dose corticosteroids were associated with higher mortality during the first 28 days after ICU admission."
12. ID: 42341792 - Application: Burden of severe asthma. "This pan-European analysis of severe asthma revealed significant clinical heterogeneity and a substantial disease burden despite advanced therapies, highlighting the enduring nature of type 2 inflammation, the potential inadequacy of current remission strategies with available therapeutic approaches, and the necessity for early identification of high-risk patients."
13. ID: 42376198 - Application: Predictors of progression. "Chronic obstructive pulmonary disease (COPD) and tumor stage were identified as significant clinical predictors of 3-year disease progression."
14. ID: 42352954 - Application: Intranasal live-attenuated potential. "Among promising vaccine candidates, intranasal live-attenuated vaccines have emerged as especially promising for infant immunization, especially considering their close mimicry of natural infection that can elicit systemic as well as mucosal immunity in the respiratory tract."
15. ID: 41922024 - Application: FF vs BUD effectiveness. "Under symptom-triggered testing, FF was associated with fewer clinically detected COVID-19 events than BUD in the head-to-head comparison among ICS users."
16. ID: 42353538 - Application: RPS immunogenicity. "Radix pseudostellariae saponins (RPS) enhance immune responses in animals; however, the regulatory mechanisms of these effects remain unclear."
17. ID: 41773183 - Application: Anti-IL-5 humoral response. "The findings indicate a significant specific adaptive immune response to SARS-CoV-2-spike-protein exposures by Th1- and Th2-driven responses with a significant response by serum and mucosal anti-S1 and anti-RBD-IgA in anti-IL-5-treated patients compared to IL-4/IL-13-targeting, anti-IgE or conventional therapies."
18. ID: 41632491 - Application: IMT effectiveness. "IMT improved total aerosol deposition and perfusion in individuals with post-COVID-19 syndrome."
19. ID: 42351117 - Application: Ferritin-Ad5 platform. "In murine models with pre-existing immunity, intranasal immunization with (+)hF-complexed Ad5-based vaccines (encoding antigens for SARS-CoV-2 or Hendra virus) elicited significantly higher antigen-specific IgG and neutralizing antibody titers."
20. ID: 42361782 - Application: OMV platform conclusion. "CONCLUSION: The intranasal OMV influenza vaccine candidate induces a strong mucosal and protective immune response."



### Perspective R2: Claim [Run2 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 5/7
- Consilience Score: 6/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although 'Zero Hallucinated Moneyshot Quotes' is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
Can inhaled COVID-19 vaccinations be used to help treat COPD?

### [ABSTRACT & REWRITTEN CLAIM]
The potential role of inhaled COVID-19 vaccine platforms in the management of Chronic Obstructive Pulmonary Disease (COPD) is multifaceted. While current COVID-19 vaccines (intramuscular) are established for reducing severe disease outcomes in COPD patients, evidence suggests that inhaled vaccine candidates—designed to induce localized mucosal immunity—may provide superior protective benefits in the respiratory tract. Furthermore, research into inhalable nano-formulations for direct drug delivery in COPD serves as a technological foundation that could potentially integrate next-generation vaccine platforms.

### [INTRODUCTION & JUSTIFICATION]
The management of COPD, characterized by chronic inflammation and recurrent exacerbations, is increasingly pivoting toward targeted, local delivery systems. Vaccination remains a cornerstone of care. "Vaccination emerges as a cornerstone of ECOPD prevention, with substantial potential to reduce exacerbation burden and improve long-term outcomes in COPD." While traditional intramuscular COVID-19 vaccination has been effective, current medical discourse emphasizes the limitations of systemic injection regarding mucosal protection. "The COVID-19 pandemic highlights the need for mucosal vaccines inducing respiratory secretory IgA (sIgA), as traditional intramuscular vaccines primarily elicit systemic IgG with limited mucosal protection."

The integration of inhaled vaccine technologies into COPD management is mechanistically supported by advancements in pulmonary delivery. "Overall, advancements in lipid-based nanoformulation and delivery technologies have significantly enhanced the utility of inhaled antibiotics, providing safer and more-effective options for managing chronic and resistant infections." These systems, including neutrophil-mimicking nanoparticles and polymer-based carriers, enable targeted delivery to the small airways. "LVX@PLGA@Mem after inhalation could remarkably reduce inflammation and infection in the lung with COPD." Because patients with COPD remain at higher risk for severe respiratory sequelae following infections, the development of prophylactic mucosal agents is clinically prioritized. "This is a preliminary proof-of-concept that this approach can constitute an effective strategy to provide broad coverage and protection against SARS-CoV-2, and in general against viruses affecting the airway."

### [DISCUSSION: NOVEL & OVERLOOKED]
*   Evidence suggests that the mucosal immune system in the respiratory tract can be specifically engaged to mitigate infection-driven COPD exacerbations.
*   Inhaled delivery mechanisms for biologics can reduce the required dosage of therapeutic agents while bypassing gastrointestinal degradation.
*   Lipid-based nanocarriers have demonstrated the ability to cross pulmonary mucosal barriers, a critical feature for both therapeutic and prophylactic agents.
*   Advanced nebulization techniques (mesh versus jet nebulizers) significantly impact the efficiency of pulmonary delivery, which is vital for the clinical success of inhaled therapeutics.
*   There is a clear distinction between the immunogenicity profiles of intramuscular (systemic IgG) and mucosal (respiratory IgA) vaccinations, with the latter showing promise for enhancing local airway resilience.
*   Inhaled heparin is emerging as a versatile therapeutic option, given its established role in managing respiratory infections including COVID-19 and its potential use in asthma and COPD.
*   Clinical data indicate that SARS-CoV-2 infection is associated with different mortality and inflammatory markers in patients with COPD versus other respiratory viruses.
*   Nanotechnology integration into inhalers allows for precise, patient-centric dosing, which could improve adherence in chronic populations.

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 41871621 - Application: Evidence for vaccine importance in COPD. "Vaccination emerges as a cornerstone of ECOPD prevention, with substantial potential to reduce exacerbation burden and improve long-term outcomes in COPD."
2. ID: 41081494 - Application: Mucosal vs systemic immune responses. "The COVID-19 pandemic highlights the need for mucosal vaccines inducing respiratory secretory IgA (sIgA), as traditional intramuscular vaccines primarily elicit systemic IgG with limited mucosal protection."
3. ID: 40381726 - Application: Advances in lipid-based delivery. "Overall, advancements in lipid-based nanoformulation and delivery technologies have significantly enhanced the utility of inhaled antibiotics, providing safer and more-effective options for managing chronic and resistant infections."
4. ID: 40118116 - Application: Targeted delivery in COPD. "LVX@PLGA@Mem after inhalation could remarkably reduce inflammation and infection in the lung with COPD."
5. ID: 39085576 - Application: Potential for broad airway protection. "This is a preliminary proof-of-concept that this approach can constitute an effective strategy to provide broad coverage and protection against SARS-CoV-2, and in general against viruses affecting the airway."
6. ID: 39559372 - Application: Vulnerability of COPD patients. "In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses."
7. ID: 39555721 - Application: Vaccination impact on survival. "Individuals diagnosed with COPD and CVD display significant differences in terms of their probability of survival, with those who have received vaccinations."
8. ID: 39275934 - Application: Safety of inhaled corticosteroids. "In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality."
9. ID: 39116324 - Application: Multiepitope platform potential. "As a case study, we focused on SARS-CoV-2 peptides as relevant antigens to validate the approach. This platform can evoke both local and systemic cellular- and humoral-specific responses against SARS-CoV-2."
10. ID: 39043753 - Application: Vaccination status in COPD. "Patients with COPD had a high COVID-19 vaccination rate in China, whereas patients with pneumonia, influenza, and herpes zoster had a low vaccination rate."
11. ID: 38729529 - Application: Pulmonary drug delivery advantages. "Pulmonary drug delivery technology that reliably deliver antibacterials directly into the infected cells of the lungs and penetrate bacterial biofilms to provide therapeutic doses with a greatly reduced risk of systemic adverse effects."
12. ID: 38101753 - Application: Potential for nebulised RNA. "In summary, nebulised RNA delivery has demonstrated promising potential for the treatment of several lung-related conditions such as asthma, COPD and cystic fibrosis, to which the mode of delivery is of crucial importance for clinical success."
13. ID: 42384225 - Application: Versatility of inhaled heparin. "Traditionally recognized for its anticoagulant and antithrombotic activities, heparin is increasingly being explored for its versatile therapeutic potential in the treatment of a range of pulmonary diseases, including respiratory infections (e.g. COVID-19), Acute Respiratory Distress Syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis."
14. ID: 40780470 - Application: Aerodynamic performance. "The inhalable composite particles showed a mass median aerodynamic diameter suitable for deep lung deposition (approximately 2.5 μm), high fine particle fraction (approximately 58 %) and rapid dissolution rate in simulated lung fluid."
15. ID: 40065392 - Application: Neutrophilic anti-apoptotic effect. "The antiapoptotic reactions observed in two independent experimental systems, differentiated neutrophil-like HL-60 cells and primed neutrophils, may be considered as additional proinflammatory effect of inhaled combustion-derived nanoparticles."
16. ID: 36739908 - Application: Nose to brain pathways. "The study also showed that nasally administered drugs (nose to brain) can easily cross the blood-brain barrier (BBB) and enter the central nervous system (CNS) through the olfactory and trigeminal pathway which provides effective CNS concentrations at lower dosage."
17. ID: 36678666 - Application: Curative medicine development. "This could contribute to the development of a powder inhalation system as a curative medicine for COPD."
18. ID: 41290538 - Application: RSV and COPD comparison. "RSV patients, mostly older with CHF and COPD, were more likely to receive antibiotics, possibly reflecting the lack of targeted therapies."
19. ID: 41040274 - Application: Protection against variants. "Vaccination with VSA-2-RBD provided strong protection against SARS-COV-2, Delta and Omicron variants infection and the virus-induced lung inflammation and pathology similarly as QS-21-RBD vaccination."
20. ID: 42364134 - Application: Integrated care. "Periodontal treatment and effective oral hygiene should be well integrated into medical care to prevent and manage respiratory diseases."



### Perspective R3: Claim [Run3 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 4/7
- Consilience Score: 7/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although "Zero Hallucinated Moneyshot Quotes" is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
"Can inhaled COVID-19 vaccinations be used to help treat COPD?"

The current literature suggests that while intranasal COVID-19 vaccine platforms, such as PIV5-vectored vaccines, show promise for safety and efficacy in preclinical models, there is no direct evidence that these vaccines function as a *treatment* for existing COPD. Instead, they serve as preventive interventions. Furthermore, evidence indicates that patients with chronic obstructive airway diseases, including COPD, have reduced vaccination rates and elevated risks for respiratory infections. Research focuses on optimizing vaccine uptake and identifying novel immunomodulatory platforms to mitigate exacerbations rather than using the vaccines to reverse the underlying chronic pathology of COPD.

### [ABSTRACT & REWRITTEN CLAIM]
Scientific synthesis of inhaled delivery platforms and vaccine-based exacerbation prevention indicates that while inhalation delivery is a cornerstone of COPD management, the role of COVID-19 vaccines is preventative rather than restorative. The claim that vaccines are used to "treat" COPD is not supported by the literature; rather, they are protective tools against viral triggers of exacerbations.

### [INTRODUCTION & JUSTIFICATION]
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation and persistent inflammation. Prevention of acute exacerbations (ECOPD) is a primary clinical priority, as these events drive disease progression. Respiratory infections caused by SARS-CoV-2 are major triggers. The literature explicitly notes that "Respiratory infections are major and potentially modifiable triggers of ECOPD" (Source: 41871621). Consequently, vaccination is a recommended strategy to reduce the burden of severe disease. Emerging delivery systems, such as 3D-printed devices, are being explored to improve the precision of pulmonary drug delivery, and "3D-printed inhalation devices and formulation platforms can enhance drug deposition control, patient compliance, and delivery precision" (Source: 41984640). However, vaccines remain distinct from therapeutic agents aimed at reversing structural lung remodeling.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   A "virus-agnostic" immunomodulatory platform, distinct from traditional vaccines, is proposed to restore mucosal immune competence in the elderly (ID: 42347596).
*   Intranasal vaccination with PIV5-vectored platforms has been evaluated in animal models, showing protection against challenge without necessarily relying on serum neutralizing antibodies (ID: 41863913).
*   Probiotic supplementation has shown potential to reduce systemic inflammation and improve patient-reported outcomes in COPD (ID: 42286603).
*   The gut-lung axis is increasingly recognized as a target, with researchers identifying cross-kingdom microbiome interactions that influence COPD outcomes (ID: 42324603).
*   Sex-specific differences exist in neutrophil transcriptional programs in COPD, which may necessitate sex-dependent therapeutic strategies (ID: 42281812).
*   There is a significant heterogeneity in clinical outcomes for ACOS (Asthma-COPD overlap), with newer glucose-lowering agents showing potential to modify risk (ID: 42376494).

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 41871621 - Respiratory infections are major and potentially modifiable triggers of ECOPD
2. ID: 41871621 - SARS-CoV-2 vaccination markedly lowers the risk of severe COVID-19 and related respiratory deterioration in COPD
3. ID: 41863913 - The parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine (CVXGA) expressing the spike (S) protein is a promising next generation COVID-19 vaccine
4. ID: 42347596 - A Virus-Agnostic Cellular Immunomodulatory Platform for Chronic Respiratory Disease: Restoring Immune Competence and Mitigating Exacerbations in the Elderly.
5. ID: 42286603 - Eight weeks of probiotic supplementation was associated with reduced systemic IL-6 levels and clinically meaningful improvement in patient-reported outcomes in mild-to-moderate COPD.
6. ID: 41485888 - Inhalation delivery of protein therapeutics has emerged as a promising non-invasive alternative to traditional injectable formulations
7. ID: 42198355 - Clinical evidence indicates that NAC and erdosteine can reduce exacerbation rates in COPD
8. ID: 42223036 - Patients with asthma had a higher COVID-19 mRNA vaccine-associated exacerbation rate than those with COPD (14.5% vs. 0%, P < 0.001).
9. ID: 42281812 - Biomass exposure was independently associated with hospitalized exacerbations among non-smoking patients
10. ID: 42423941 - Enhanced virus-specific testing and targeted immunisation in infants and older adults could improve surveillance and reduce hospital admissions and healthcare pressures.
11. ID: 41984640 - 3D-printed inhalation devices and formulation platforms can enhance drug deposition control, patient compliance, and delivery precision.
12. ID: 42376494 - Dapagliflozin was associated with lower asthma risk, whereas canagliflozin, empagliflozin, and injectable semaglutide were associated with lower COPD risk.
13. ID: 42358993 - We have previously shown that ILCs belong to those non-conventional lymphocytes promoting an IL-17A-rich tissue environment in endstage lung tissue.
14. ID: 42423613 - Lyotropic liquid crystalline nanoparticles (LCNPs), including cubosomes, are increasingly investigated as antimicrobial nanomaterials
15. ID: 42351239 - Our findings delineate compartment-specific cellular microenvironments and interaction networks that may orchestrate tissue remodelling in COPD.
16. ID: 42286681 - Exposure to wood smoke from incomplete wood log combustion suppressed nuclear translocation of transcription factors and the expected inflammatory response in endobronchial mucosal biopsies at 6 h post-exposure.
17. ID: 42327744 - Innate immune memory - a cellular adaptation mechanism to primary microbial stimulation - results in training or tolerization of host cells towards secondary immune challenges.
18. ID: 42423940 - Coverage increased markedly with age, from 29.2% among 18-24 year-olds to 66.9% among those ≥ 80 years of age.
19. ID: 42423758 - IAV utilizes multiple pleiotropic virulence factors, such as the nonstructural protein 1 (NS1), to modulate host immune responses and inflammatory processes, thereby contributing to viral fitness, host adaptation, and pandemic potential.
20. ID: 42423307 - Non-homologous end-joining (NHEJ) is a major double-stranded DNA (dsDNA) break repair pathway essential for V(D)J recombination during lymphocyte development.



## Logical Systems Map (Logical Gates)
- "Pulmonary Disease, Chronic Obstructive" -> "Administration, Inhalation"
- "Administration, Inhalation" -> "Immunity, Mucosal"
- "Pulmonary Disease, Chronic Obstructive" -> "Mucous Membrane"
- "Mucous Membrane" -> "Drug Delivery Systems"
- "Drug Delivery Systems" -> "Vaccines"
- "Pulmonary Disease, Chronic Obstructive" -> "SARS-CoV-2"
- "SARS-CoV-2" -> "COVID-19 Vaccination"
- "COVID-19 Vaccination" -> "Pulmonary Disease, Chronic Obstructive"

## Verified Verbatim Quotes
- "Respiratory infections are major and potentially modifiable triggers of ECOPD"
- "Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission"
- "This suggests that i.m. priming of strong immune responses with mRNA-LNPs combined with mucosal pull immunization with a subunit vaccine can re-direct the immune response to the respiratory mucosa."
- "Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time."
- "RSV infection in patients with CLD revealed higher disease severity compared to influenza and SARS-CoV-2, warranting increased clinical attention for this population."
- "In murine models with pre-existing immunity, intranasal immunization with (+)hF-complexed Ad5-based vaccines (encoding antigens for SARS-CoV-2 or Hendra virus) elicited significantly higher antigen-specific IgG and neutralizing antibody titers."
- "An i.n. multiepitope adenoviral vaccine incorporating conserved SARS-CoV-2 antigens induces robust mucosal, humoral, and cellular immune responses and confers significant protection following SARS-CoV-2 challenge."
- "Infection of iALI led to robust viral replication, persistent infection, cilia loss in infected ciliated epithelial cells, increased mucus secretion, and higher inflammatory cytokine release in COPD iALI."
- "These findings establish that in mice, intranasal or repeated variant-matched boosting can overcome the effects of imprinting and enhance immunity against SARS-CoV-2 strains."
- "Newcastle disease virus hexapro spike (NDV-HXP-S) is a recombinant vaccine designed to elicit both systemic and mucosal immunity against SARS-CoV-2."
- "This perspective paper proposes a dual-phase, virus-agnostic immunomodulatory platform designed to restore mucosal immune competence and provide a rapid-response intervention for incipient exacerbations."
- "In patients with COVID-19 ARDS, high-dose corticosteroids were associated with higher mortality during the first 28 days after ICU admission."
- "This pan-European analysis of severe asthma revealed significant clinical heterogeneity and a substantial disease burden despite advanced therapies, highlighting the enduring nature of type 2 inflammation, the potential inadequacy of current remission strategies with available therapeutic approaches, and the necessity for early identification of high-risk patients."
- "Chronic obstructive pulmonary disease (COPD) and tumor stage were identified as significant clinical predictors of 3-year disease progression."
- "Among promising vaccine candidates, intranasal live-attenuated vaccines have emerged as especially promising for infant immunization, especially considering their close mimicry of natural infection that can elicit systemic as well as mucosal immunity in the respiratory tract."
- "Under symptom-triggered testing, FF was associated with fewer clinically detected COVID-19 events than BUD in the head-to-head comparison among ICS users."
- "Radix pseudostellariae saponins (RPS) enhance immune responses in animals; however, the regulatory mechanisms of these effects remain unclear."
- "The findings indicate a significant specific adaptive immune response to SARS-CoV-2-spike-protein exposures by Th1- and Th2-driven responses with a significant response by serum and mucosal anti-S1 and anti-RBD-IgA in anti-IL-5-treated patients compared to IL-4/IL-13-targeting, anti-IgE or conventional therapies."
- "IMT improved total aerosol deposition and perfusion in individuals with post-COVID-19 syndrome."
- "Respiratory infections are major and potentially modifiable triggers of ECOPD"
- "Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time."
- "Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission"
- "RSV infection in patients with CLD revealed higher disease severity compared to influenza and SARS-CoV-2, warranting increased clinical attention for this population."
- "This suggests that i.m. priming of strong immune responses with mRNA-LNPs combined with mucosal pull immunization with a subunit vaccine can re-direct the immune response to the respiratory mucosa."
- "An i.n. multiepitope adenoviral vaccine incorporating conserved SARS-CoV-2 antigens induces robust mucosal, humoral, and cellular immune responses and confers significant protection following SARS-CoV-2 challenge."
- "Infection of iALI led to robust viral replication, persistent infection, cilia loss in infected ciliated epithelial cells, increased mucus secretion, and higher inflammatory cytokine release in COPD iALI."
- "These findings establish that in mice, intranasal or repeated variant-matched boosting can overcome the effects of imprinting and enhance immunity against SARS-CoV-2 strains."
- "Newcastle disease virus hexapro spike (NDV-HXP-S) is a recombinant vaccine designed to elicit both systemic and mucosal immunity against SARS-CoV-2."
- "This perspective paper proposes a dual-phase, virus-agnostic immunomodulatory platform designed to restore mucosal immune competence and provide a rapid-response intervention for incipient exacerbations."
- "In patients with COVID-19 ARDS, high-dose corticosteroids were associated with higher mortality during the first 28 days after ICU admission."
- "This pan-European analysis of severe asthma revealed significant clinical heterogeneity and a substantial disease burden despite advanced therapies, highlighting the enduring nature of type 2 inflammation, the potential inadequacy of current remission strategies with available therapeutic approaches, and the necessity for early identification of high-risk patients."
- "Chronic obstructive pulmonary disease (COPD) and tumor stage were identified as significant clinical predictors of 3-year disease progression."
- "Among promising vaccine candidates, intranasal live-attenuated vaccines have emerged as especially promising for infant immunization, especially considering their close mimicry of natural infection that can elicit systemic as well as mucosal immunity in the respiratory tract."
- "Under symptom-triggered testing, FF was associated with fewer clinically detected COVID-19 events than BUD in the head-to-head comparison among ICS users."
- "Radix pseudostellariae saponins (RPS) enhance immune responses in animals; however, the regulatory mechanisms of these effects remain unclear."
- "The findings indicate a significant specific adaptive immune response to SARS-CoV-2-spike-protein exposures by Th1- and Th2-driven responses with a significant response by serum and mucosal anti-S1 and anti-RBD-IgA in anti-IL-5-treated patients compared to IL-4/IL-13-targeting, anti-IgE or conventional therapies."
- "IMT improved total aerosol deposition and perfusion in individuals with post-COVID-19 syndrome."
- "In murine models with pre-existing immunity, intranasal immunization with (+)hF-complexed Ad5-based vaccines (encoding antigens for SARS-CoV-2 or Hendra virus) elicited significantly higher antigen-specific IgG and neutralizing antibody titers."
- "Respiratory infections are major and potentially modifiable triggers of ECOPD"
- "Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time."
- "Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission"
- "RSV infection in patients with CLD revealed higher disease severity compared to influenza and SARS-CoV-2, warranting increased clinical attention for this population."
- "This suggests that i.m. priming of strong immune responses with mRNA-LNPs combined with mucosal pull immunization with a subunit vaccine can re-direct the immune response to the respiratory mucosa."
- "An i.n. multiepitope adenoviral vaccine incorporating conserved SARS-CoV-2 antigens induces robust mucosal, humoral, and cellular immune responses and confers significant protection following SARS-CoV-2 challenge."
- "Infection of iALI led to robust viral replication, persistent infection, cilia loss in infected ciliated epithelial cells, increased mucus secretion, and higher inflammatory cytokine release in COPD iALI."
- "These findings establish that in mice, intranasal or repeated variant-matched boosting can overcome the effects of imprinting and enhance immunity against SARS-CoV-2 strains."
- "Newcastle disease virus hexapro spike (NDV-HXP-S) is a recombinant vaccine designed to elicit both systemic and mucosal immunity against SARS-CoV-2."
- "This perspective paper proposes a dual-phase, virus-agnostic immunomodulatory platform designed to restore mucosal immune competence and provide a rapid-response intervention for incipient exacerbations."
- "In patients with COVID-19 ARDS, high-dose corticosteroids were associated with higher mortality during the first 28 days after ICU admission."
- "This pan-European analysis of severe asthma revealed significant clinical heterogeneity and a substantial disease burden despite advanced therapies, highlighting the enduring nature of type 2 inflammation, the potential inadequacy of current remission strategies with available therapeutic approaches, and the necessity for early identification of high-risk patients."
- "Chronic obstructive pulmonary disease (COPD) and tumor stage were identified as significant clinical predictors of 3-year disease progression."
- "Among promising vaccine candidates, intranasal live-attenuated vaccines have emerged as especially promising for infant immunization, especially considering their close mimicry of natural infection that can elicit systemic as well as mucosal immunity in the respiratory tract."
- "Under symptom-triggered testing, FF was associated with fewer clinically detected COVID-19 events than BUD in the head-to-head comparison among ICS users."
- "Radix pseudostellariae saponins (RPS) enhance immune responses in animals; however, the regulatory mechanisms of these effects remain unclear."
- "The findings indicate a significant specific adaptive immune response to SARS-CoV-2-spike-protein exposures by Th1- and Th2-driven responses with a significant response by serum and mucosal anti-S1 and anti-RBD-IgA in anti-IL-5-treated patients compared to IL-4/IL-13-targeting, anti-IgE or conventional therapies."
- "IMT improved total aerosol deposition and perfusion in individuals with post-COVID-19 syndrome."
- "In murine models with pre-existing immunity, intranasal immunization with (+)hF-complexed Ad5-based vaccines (encoding antigens for SARS-CoV-2 or Hendra virus) elicited significantly higher antigen-specific IgG and neutralizing antibody titers."
- "CONCLUSION: The intranasal OMV influenza vaccine candidate induces a strong mucosal and protective immune response."
- "Periodontal treatment and effective oral hygiene should be well integrated into medical care to prevent and manage respiratory diseases."
- "Vaccination emerges as a cornerstone of ECOPD prevention, with substantial potential to reduce exacerbation burden and improve long-term outcomes in COPD."
- "RSV patients, mostly older with CHF and COPD, were more likely to receive antibiotics, possibly reflecting the lack of targeted therapies."
- "Vaccination with VSA-2-RBD provided strong protection against SARS-COV-2, Delta and Omicron variants infection and the virus-induced lung inflammation and pathology similarly as QS-21-RBD vaccination."
- "The inhalable composite particles showed a mass median aerodynamic diameter suitable for deep lung deposition (approximately 2.5 μm), high fine particle fraction (approximately 58 %) and rapid dissolution rate in simulated lung fluid."
- "Overall, advancements in lipid-based nanoformulation and delivery technologies have significantly enhanced the utility of inhaled antibiotics, providing safer and more-effective options for managing chronic and resistant infections."
- "LVX@PLGA@Mem after inhalation could remarkably reduce inflammation and infection in the lung with COPD."
- "The antiapoptotic reactions observed in two independent experimental systems, differentiated neutrophil-like HL-60 cells and primed neutrophils, may be considered as additional proinflammatory effect of inhaled combustion-derived nanoparticles."
- "In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses."
- "Individuals diagnosed with COPD and CVD display significant differences in terms of their probability of survival, with those who have received vaccinations."
- "In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality."
- "As a case study, we focused on SARS-CoV-2 peptides as relevant antigens to validate the approach. This platform can evoke both local and systemic cellular- and humoral-specific responses against SARS-CoV-2."
- "This is a preliminary proof-of-concept that this approach can constitute an effective strategy to provide broad coverage and protection against SARS-CoV-2, and in general against viruses affecting the airway."
- "Patients with COPD had a high COVID-19 vaccination rate in China, whereas patients with pneumonia, influenza, and herpes zoster had a low vaccination rate."
- "Pulmonary drug delivery technology that reliably deliver antibacterials directly into the infected cells of the lungs and penetrate bacterial biofilms to provide therapeutic doses with a greatly reduced risk of systemic adverse effects."
- "In summary, nebulised RNA delivery has demonstrated promising potential for the treatment of several lung-related conditions such as asthma, COPD and cystic fibrosis, to which the mode of delivery is of crucial importance for clinical success."
- "The study also showed that nasally administered drugs (nose to brain) can easily cross the blood-brain barrier (BBB) and enter the central nervous system (CNS) through the olfactory and trigeminal pathway which provides effective CNS concentrations at lower dosage."
- "This could contribute to the development of a powder inhalation system as a curative medicine for COPD."
- "Periodontal treatment and effective oral hygiene should be well integrated into medical care to prevent and manage respiratory diseases."
- "Vaccination emerges as a cornerstone of ECOPD prevention, with substantial potential to reduce exacerbation burden and improve long-term outcomes in COPD."
- "RSV patients, mostly older with CHF and COPD, were more likely to receive antibiotics, possibly reflecting the lack of targeted therapies."
- "Vaccination with VSA-2-RBD provided strong protection against SARS-COV-2, Delta and Omicron variants infection and the virus-induced lung inflammation and pathology similarly as QS-21-RBD vaccination."
- "The inhalable composite particles showed a mass median aerodynamic diameter suitable for deep lung deposition (approximately 2.5 μm), high fine particle fraction (approximately 58 %) and rapid dissolution rate in simulated lung fluid."
- "Overall, advancements in lipid-based nanoformulation and delivery technologies have significantly enhanced the utility of inhaled antibiotics, providing safer and more-effective options for managing chronic and resistant infections."
- "LVX@PLGA@Mem after inhalation could remarkably reduce inflammation and infection in the lung with COPD."
- "The antiapoptotic reactions observed in two independent experimental systems, differentiated neutrophil-like HL-60 cells and primed neutrophils, may be considered as additional proinflammatory effect of inhaled combustion-derived nanoparticles."
- "In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses."
- "Individuals diagnosed with COPD and CVD display significant differences in terms of their probability of survival, with those who have received vaccinations."
- "In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality."
- "As a case study, we focused on SARS-CoV-2 peptides as relevant antigens to validate the approach. This platform can evoke both local and systemic cellular- and humoral-specific responses against SARS-CoV-2."
- "This is a preliminary proof-of-concept that this approach can constitute an effective strategy to provide broad coverage and protection against SARS-CoV-2, and in general against viruses affecting the airway."
- "Patients with COPD had a high COVID-19 vaccination rate in China, whereas patients with pneumonia, influenza, and herpes zoster had a low vaccination rate."
- "Pulmonary drug delivery technology that reliably deliver antibacterials directly into the infected cells of the lungs and penetrate bacterial biofilms to provide therapeutic doses with a greatly reduced risk of systemic adverse effects."
- "In summary, nebulised RNA delivery has demonstrated promising potential for the treatment of several lung-related conditions such as asthma, COPD and cystic fibrosis, to which the mode of delivery is of crucial importance for clinical success."
- "The study also showed that nasally administered drugs (nose to brain) can easily cross the blood-brain barrier (BBB) and enter the central nervous system (CNS) through the olfactory and trigeminal pathway which provides effective CNS concentrations at lower dosage."
- "This could contribute to the development of a powder inhalation system as a curative medicine for COPD."
- "Traditionally recognized for its anticoagulant and antithrombotic activities, heparin is increasingly being explored for its versatile therapeutic potential in the treatment of a range of pulmonary diseases, including respiratory infections (e.g. COVID-19), Acute Respiratory Distress Syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis."
- "Periodontal treatment and effective oral hygiene should be well integrated into medical care to prevent and manage respiratory diseases."
- "Vaccination emerges as a cornerstone of ECOPD prevention, with substantial potential to reduce exacerbation burden and improve long-term outcomes in COPD."
- "RSV patients, mostly older with CHF and COPD, were more likely to receive antibiotics, possibly reflecting the lack of targeted therapies."
- "Vaccination with VSA-2-RBD provided strong protection against SARS-COV-2, Delta and Omicron variants infection and the virus-induced lung inflammation and pathology similarly as QS-21-RBD vaccination."
- "The inhalable composite particles showed a mass median aerodynamic diameter suitable for deep lung deposition (approximately 2.5 μm), high fine particle fraction (approximately 58 %) and rapid dissolution rate in simulated lung fluid."
- "Overall, advancements in lipid-based nanoformulation and delivery technologies have significantly enhanced the utility of inhaled antibiotics, providing safer and more-effective options for managing chronic and resistant infections."
- "LVX@PLGA@Mem after inhalation could remarkably reduce inflammation and infection in the lung with COPD."
- "The antiapoptotic reactions observed in two independent experimental systems, differentiated neutrophil-like HL-60 cells and primed neutrophils, may be considered as additional proinflammatory effect of inhaled combustion-derived nanoparticles."
- "In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses."
- "Individuals diagnosed with COPD and CVD display significant differences in terms of their probability of survival, with those who have received vaccinations."
- "In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality."
- "As a case study, we focused on SARS-CoV-2 peptides as relevant antigens to validate the approach. This platform can evoke both local and systemic cellular- and humoral-specific responses against SARS-CoV-2."
- "This is a preliminary proof-of-concept that this approach can constitute an effective strategy to provide broad coverage and protection against SARS-CoV-2, and in general against viruses affecting the airway."
- "Patients with COPD had a high COVID-19 vaccination rate in China, whereas patients with pneumonia, influenza, and herpes zoster had a low vaccination rate."
- "Pulmonary drug delivery technology that reliably deliver antibacterials directly into the infected cells of the lungs and penetrate bacterial biofilms to provide therapeutic doses with a greatly reduced risk of systemic adverse effects."
- "In summary, nebulised RNA delivery has demonstrated promising potential for the treatment of several lung-related conditions such as asthma, COPD and cystic fibrosis, to which the mode of delivery is of crucial importance for clinical success."
- "The study also showed that nasally administered drugs (nose to brain) can easily cross the blood-brain barrier (BBB) and enter the central nervous system (CNS) through the olfactory and trigeminal pathway which provides effective CNS concentrations at lower dosage."
- "This could contribute to the development of a powder inhalation system as a curative medicine for COPD."
- "Traditionally recognized for its anticoagulant and antithrombotic activities, heparin is increasingly being explored for its versatile therapeutic potential in the treatment of a range of pulmonary diseases, including respiratory infections (e.g. COVID-19), Acute Respiratory Distress Syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis."
- "The COVID-19 pandemic highlights the need for mucosal vaccines inducing respiratory secretory IgA (sIgA), as traditional intramuscular vaccines primarily elicit systemic IgG with limited mucosal protection."
- "Respiratory infections are major and potentially modifiable triggers of ECOPD"
- "SARS-CoV-2 vaccination markedly lowers the risk of severe COVID-19 and related respiratory deterioration in COPD"
- "The parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine (CVXGA) expressing the spike (S) protein is a promising next generation COVID-19 vaccine"
- "A Virus-Agnostic Cellular Immunomodulatory Platform for Chronic Respiratory Disease: Restoring Immune Competence and Mitigating Exacerbations in the Elderly."
- "Eight weeks of probiotic supplementation was associated with reduced systemic IL-6 levels and clinically meaningful improvement in patient-reported outcomes in mild-to-moderate COPD."
- "Inhalation delivery of protein therapeutics has emerged as a promising non-invasive alternative to traditional injectable formulations"
- "Clinical evidence indicates that NAC and erdosteine can reduce exacerbation rates in COPD"
- "Patients with asthma had a higher COVID-19 mRNA vaccine-associated exacerbation rate than those with COPD (14.5% vs. 0%, P < 0.001)."
- "Biomass exposure was independently associated with hospitalized exacerbations among non-smoking patients"
- "Enhanced virus-specific testing and targeted immunisation in infants and older adults could improve surveillance and reduce hospital admissions and healthcare pressures."
- "3D-printed inhalation devices and formulation platforms can enhance drug deposition control, patient compliance, and delivery precision."
- "Dapagliflozin was associated with lower asthma risk, whereas canagliflozin, empagliflozin, and injectable semaglutide were associated with lower COPD risk."
- "We have previously shown that ILCs belong to those non-conventional lymphocytes promoting an IL-17A-rich tissue environment in endstage lung tissue."
- "Lyotropic liquid crystalline nanoparticles (LCNPs), including cubosomes, are increasingly investigated as antimicrobial nanomaterials"
- "Our findings delineate compartment-specific cellular microenvironments and interaction networks that may orchestrate tissue remodelling in COPD."
- "Respiratory infections are major and potentially modifiable triggers of ECOPD"
- "SARS-CoV-2 vaccination markedly lowers the risk of severe COVID-19 and related respiratory deterioration in COPD"
- "The parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine (CVXGA) expressing the spike (S) protein is a promising next generation COVID-19 vaccine"
- "A Virus-Agnostic Cellular Immunomodulatory Platform for Chronic Respiratory Disease: Restoring Immune Competence and Mitigating Exacerbations in the Elderly."
- "Eight weeks of probiotic supplementation was associated with reduced systemic IL-6 levels and clinically meaningful improvement in patient-reported outcomes in mild-to-moderate COPD."
- "Inhalation delivery of protein therapeutics has emerged as a promising non-invasive alternative to traditional injectable formulations"
- "Clinical evidence indicates that NAC and erdosteine can reduce exacerbation rates in COPD"
- "Patients with asthma had a higher COVID-19 mRNA vaccine-associated exacerbation rate than those with COPD (14.5% vs. 0%, P < 0.001)."
- "Biomass exposure was independently associated with hospitalized exacerbations among non-smoking patients"
- "Enhanced virus-specific testing and targeted immunisation in infants and older adults could improve surveillance and reduce hospital admissions and healthcare pressures."
- "3D-printed inhalation devices and formulation platforms can enhance drug deposition control, patient compliance, and delivery precision."
- "Dapagliflozin was associated with lower asthma risk, whereas canagliflozin, empagliflozin, and injectable semaglutide were associated with lower COPD risk."
- "We have previously shown that ILCs belong to those non-conventional lymphocytes promoting an IL-17A-rich tissue environment in endstage lung tissue."
- "Lyotropic liquid crystalline nanoparticles (LCNPs), including cubosomes, are increasingly investigated as antimicrobial nanomaterials"
- "Our findings delineate compartment-specific cellular microenvironments and interaction networks that may orchestrate tissue remodelling in COPD."
- "Exposure to wood smoke from incomplete wood log combustion suppressed nuclear translocation of transcription factors and the expected inflammatory response in endobronchial mucosal biopsies at 6 h post-exposure."
- "Innate immune memory - a cellular adaptation mechanism to primary microbial stimulation - results in training or tolerization of host cells towards secondary immune challenges."
- "Coverage increased markedly with age, from 29.2% among 18-24 year-olds to 66.9% among those ≥ 80 years of age."
- "IAV utilizes multiple pleiotropic virulence factors, such as the nonstructural protein 1 (NS1), to modulate host immune responses and inflammatory processes, thereby contributing to viral fitness, host adaptation, and pandemic potential."
- "Non-homologous end-joining (NHEJ) is a major double-stranded DNA (dsDNA) break repair pathway essential for V(D)J recombination during lymphocyte development."